Comparative study of uniform-MDT and WHO-MDT in pauci and multi bacillary leprosy patients over 18 months of observation


  • Neha Rani Department of Dermatology, Central Coalfield Limited Hospital, Ramgarh, Jharkhand, India
  • Somnath Mukherjee Department of Cardiology, IPGMER, Kolkata, West Bengal, India
  • Prashant Kumar Department of Cardiology, RIMS, Ranchi, Jharkhand, India
  • Shyam Sundar Choudhary Department of Dermatology, RIMS, Ranchi, Jharkhand, India



Pauci and multibacillary leprosy, U- MDT, WHO- MDT


Background: To determine the efficacy of the current WHO-MDT and U-MDT regimen with regard to relapse rate and acceptability of the patients and to compare both regimen in pauci and multi bacillary cases.

Methods: Total of 106 leprosy patients aged between 14-60 years attending department of Dermatology, Venerology and Leprosy at RIMS, Ranchi between May 2011 and October 2012 were included in the study and they were allocated alternatively into two groups, U-MDT and WHO-MDT. Patients were followed up for 12 to 18 months for periodic clinical, bacteriological and histopathological assessment.

Results: In histopathological assessment of PB cases, after 6, 12 and 18 months, UPB group showed 91%, 100% and 100% improvement as compared to 77.5%, 86.5% and 95.2% in WPB group. Among multi bacillary cases, after 12 months 32% of UMB group of patients became smear negative whereas in WMB group 48% became smear negative. In histopathological assessment after 12 months, in UMB group, 94% patients showed good improvement whereas in WMB group only 77% patients showed good improvement. After 18 months, in UMB group, 50% patients deteriorated and showed poor improvement whereas almost 100% patients showed good improvements in WMB group.

Conclusions: In conclusion, U-MDT was observed to be an effective and useful regimen to treat PB patients of leprosy, but in MB patients it was not found to be very effective regimen when compared to WHO-MDT of 12 months duration. Mere acceptability factor of the U-MDT regimen cannot be sufficient for its routine implementation in the general health service.


Ridéey D, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Leprosy. 1966;34(3):255-73.

WHO. A guide to eliminating leprosy as a public health problem. 2nd ed. Geneva, World Health Organization. 1997. (WHO/LEP/97.1).

WHO. Report on the third meeting of the WHO technical advisory group on elimination of leprosy. Geneva, World Health Organization. 2002 (WHO/CDS/CPE/CEE/2002.29).

Arora M, Katoch K, Natrajan M, Kamal R, Yadav VS. Changing profile of disease in leprosy patients diagnosed in a tertiary care centre during years 1995-2000. Indian J Leprosy. 2008;80(3):257.

Mahajan VK, Sharma NL, Rana P, Sood N. Trends in detection of new leprosy cases at two centres in Himachal Pradesh, India: a ten-year study. Indian J Leprosy. 2003;75(1):17-24.

Kaur I, Dogra S, De D, Saikia UN. Histoid leprosy: a retrospective study of 40 cases from India. Br J Dermatol. 2009 Feb;160(2):305-10.

Vara N, Agarwal M, Marfatia Y. Leprosy beyond MDT. Study of follow up of 100 released from treatment cases. Indian J Lepr. 2010;82:189-94.

WHO. Uniform MDT regimen for all leprosy patients. Protocol. Geneva, World Health Organisation. 20 August 2002.

WHO study group. Chemotherapy of leprosy for control programmes. Geneva, World Health Organisation; 1982. (WHO Technical Report Series, no. 675).

WHO Expert Committee on Leprosy. 7th Report. Geneva, World Health Organisation; 1998.




How to Cite

Rani, N., Mukherjee, S., Kumar, P., & Choudhary, S. S. (2018). Comparative study of uniform-MDT and WHO-MDT in pauci and multi bacillary leprosy patients over 18 months of observation. International Journal of Research in Medical Sciences, 6(11), 3546–3551.



Original Research Articles